Close menu




September 30th, 2025 | 07:40 CEST

Antimony Resources, Rheinmetall, Novo Nordisk – Something is in the air!

  • Mining
  • antimony
  • Defense
  • Biotechnology
Photo credits: pixabay.com

Sufficient access to raw materials is crucial for any economy. The EU has compiled a list of 34 critical raw materials. How critical a raw material is classified depends on two parameters: "economic importance" and "supply risk." This list also includes a little-known but very important metalloid – antimony. The price of antimony skyrocketed at the end of 2024 in the wake of China's export ban. There are still exciting investment opportunities in this area.

time to read: 2 minutes | Author: Carsten Mainitz
ISIN: ANTIMONY RESOURCES CORP | CA0369271014 , RHEINMETALL AG | DE0007030009 , NOVO NORDISK A/S | DK0062498333

Table of contents:


    Antimony Resources – Still flying under the radar of investors

    Antimony is versatile and in high demand: its applications as a flame retardant, in photovoltaics, defense, semiconductors, and energy storage highlight its importance. As with many other critical metals and rare earths, China dominates global supply. At the end of last year, the country imposed a global export ban. This shines a spotlight on future producers, such as Antimony Resources.

    The Canadians have the option to acquire the Bald Hill property in southern New Brunswick, Canada. Previous drilling has identified antimony over a length of more than 700 m and a depth of 400 m with an average thickness of over 3 m and a grade of 3% to 4% antimony (Sb). This distinguishes Bald Hill as a first-class, high-grade antimony deposit.

    The current drilling program, which could give the stock a significant boost, is divided into several phases. A total of at least 6,000 meters of drilling is to be completed. Phase 1 at Bald Hill has already delivered good results. Significant high-grade antimony deposits were intersected in over 75% of the drill holes. The previously defined main mineralization zone was also significantly expanded.

    The Company has now announced the start of the second phase of its drilling program, with two main priorities. The first is to extend the known antimony-bearing mineralization to the north and south and to expand the mineralization at depth. This trend has already been successfully demonstrated in Phase 1.

    The second priority is to drill at locations that demonstrate a connection between widely separated mineralization zones. The aim is to determine whether the mineralization is sufficiently continuous and whether sufficient data is available.

    Rheinmetall – Above the EUR 2000 mark for the first time

    As mentioned above, antimony plays an important role in the defense industry. This semi-metal increases the hardness and stability of lead and is therefore essential in the manufacture of ammunition and armor. Antimony is also used in high-tech weapons, night vision devices, and infrared sensors.

    German defense stocks continued their rally at the beginning of the week, reaching new all-time highs. Rheinmetall shares climbed slightly above the EUR 2,000 mark for the first time. Although the shares have already increased twentyfold since the start of the war in Ukraine, analysts at UBS and mwb research still see room for growth up to EUR 2,500.

    The enormous demand for weapon systems and ammunition continues to swell order books. The DAX-listed company recently announced that it would be supplying ammunition to Eastern Europe as a subcontractor to a company commissioned by the US government. The total value of the order is in the mid three-digit million range.

    Novo Nordisk – Negative analyst opinion weighs on the stock in the short term

    A significant downgrade by Morgan Stanley to "Underweight", coupled with a price target capped at EUR 40, weighed on the stock in the short term. Analysts expect minimal growth in revenue and profits next year and point to the Danish company's challenging competitive position.

    The shares are currently trading at around EUR 47 and have already priced in many negative factors. At first glance, the stock appears undervalued historically, but growth remains subdued. Investors are not missing out on anything yet and can monitor developments from the sidelines.


    If Antimony Resources' current drilling program proves successful, as initial data suggests, this could give the share price a significant boost. The market capitalization is just CAD 11 million. Rheinmetall is benefiting from sustained high demand and still has room for growth despite reaching an all-time high. A lot of negative factors are already priced into Novo Nordisk's share price.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Carsten Mainitz

    Carsten Mainitz

    The native Rhineland-Palatinate has been a passionate market participant for more than 25 years. After studying business administration in Mannheim, he worked as a journalist, in equity sales and many years in equity research.

    About the author



    Related comments:

    Commented by Jens Castner on October 30th, 2026 | 05:45 CET

    When the stock market gets it wrong: Schott Pharma clears its name; Lahontan Gold and Instone are the next candidates

    • Speciality glass
    • Gold
    • Real estate
    • Chemicals
    • Silver
    • Expropriation
    • Health
    • Berlin
    • Misvaluations
    • Mining
    • Schott Pharma
    • Instone Real Estate
    • Lahontan Gold

    Markets are quick to judge, and often paint companies with a broad brush. When one company runs into difficulties, its competitors immediately come under suspicion too. Schott Pharma has already been through this and dispelled the doubts with strong figures. Its share price is recovering. For Lahontan Gold and Instone Real Estate, the recovery has yet to come. The Canadian gold explorer is being punished alongside the major producers, while the property developer is being grouped with Berlin's residential landlords. In both cases, the facts tell a different story. The share price upside is considerable.

    Read

    Commented by Tarik Dede on October 28th, 2026 | 05:43 CET

    Precious metals in turmoil: Opportunities in Hecla Mining, Desert Gold and Kinross Gold

    • Gold
    • Interest rates
    • Mining
    • KInross Gold
    • Hecla Mining
    • Desert Gold

    Created and Published on Behalf of Desert Gold Ventures Inc.

    These are wild weeks for gold and silver prices. The battle over the round USD 4,000 per ounce mark for gold is at its peak. Bulls and bears have been locked in a fierce contest for days. If the level holds, technical analysts expect a swift rebound upwards. Late autumn is also traditionally a seasonally strong period for precious metals. The market itself is already showing signs of a sell-off in gold and silver stocks, from major producers and developers to junior explorers. This opens up opportunities for bold investors. That is why today we are looking at the shares of Hecla Mining, Desert Gold and Kinross Gold.

    Read

    Commented by Tarik Dede on October 26th, 2026 | 05:24 CET

    Gold below USD 4,000: Opportunities at Newmont, Phenom Resources and Agnico Eagle

    • Gold
    • Mining
    • Interest rates
    • Stock exchange
    • Agnico
    • Newmont
    • Phenom Resources

    "Bears want to see the USD 4,000 mark", one analyst wrote last week. That is exactly what happened to gold, which ended the past week just below the psychological threshold. For technical analysts, this is no disaster, but it is weighing on sentiment in the gold sector. However, not all shares followed the move. Some stocks are now showing relative strength against the gold price. For investors with a long-term investment horizon, short-term declines may matter less. Most bank analysts share this view. Strategic investors, meanwhile, are using the lower prices to increase their holdings substantially. For example, the People's Bank of China recently purchased 26 tonnes of gold for its reserves. Against this backdrop, we take a closer look at the shares of global industry leader Newmont, Phenom Resources and Agnico Eagle.

    Read